Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

7.1%

2 terminated out of 28 trials

Success Rate

88.9%

+2.3% vs benchmark

Late-Stage Pipeline

7%

2 trials in Phase 3/4

Results Transparency

38%

6 of 16 completed with results

Key Signals

6 with results89% success

Data Visualizations

Phase Distribution

19Total
Not Applicable (9)
Early P 1 (1)
P 1 (4)
P 2 (3)
P 3 (2)

Trial Status

Completed16
Not Yet Recruiting4
Recruiting3
Terminated2
Unknown2
Suspended1

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (28)

Showing 20 of 20 trials
NCT06973772Phase 3Not Yet Recruiting

Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.

NCT04650399Phase 3CompletedPrimary

A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents

NCT07600879Not ApplicableNot Yet Recruiting

Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients

NCT07394426Early Phase 1Not Yet RecruitingPrimary

A Phase I Study of PepGNP-ChikV in Healthy Volunteers

NCT07517731Not ApplicableCompleted

Using Digital Technology for the Prevention of Aedes-Borne Diseases in Colombian Communities

NCT06595745Not ApplicableTerminated

Testing Combined IIT-SIT to Control Mosquito-Borne Diseases At Scale

NCT06669208Phase 1Completed

Trial of an Inactivated Chikungunya Virus Vaccine

NCT04838574CompletedPrimary

Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years

NCT07358910Recruiting

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

NCT04343521Not ApplicableCompleted

Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases

NCT07112846Not Yet Recruiting

Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections

NCT04566484Phase 2TerminatedPrimary

Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia

NCT06257810Not ApplicableCompleted

Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa

NCT03992872Phase 2CompletedPrimary

Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)

NCT05153018Not ApplicableCompleted

Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu

NCT04619823Not ApplicableRecruiting

Virological and Immunological Determinants of Arbovirus Infection in New Caledonia

NCT04615364Recruiting

Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia

NCT04434846Completed

Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia

NCT01099852Unknown

Cohort of Patients Infected by an Arbovirus

NCT04440774Phase 1CompletedPrimary

Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.

Scroll to load more

Research Network

Activity Timeline